期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人表皮生长因子受体2过表达乳腺癌耐药后的治疗策略

下载PDF
导出
摘要 人表皮生长因子受体2(human epidermal growth factor receptor-2,Her-2)过表达是乳腺癌患者的一个独立预后因子。曲妥珠单抗单药治疗Her-2阳性转移性乳腺癌具有一定疗效。但由于一些生长因子(如EGFR、IGF1-R)转导作用增强,以及曲妥珠单抗与Her-2的亲和力下降,一些患者会对曲妥珠单抗的抗Her-2治疗产生原发性耐药或获得性耐药。研究显示,HER-2阳性乳腺癌患者即使在曲妥珠单抗治疗进展后,继续使用曲妥珠单抗,并与化疗药物联合或更换靶向药物或采用双靶向治疗,仍可以进一步改善预后。
作者 张童童 李青
机构地区 中国医学科学院北京协和医学院肿瘤医院内科
出处 《癌症进展》 2014年第5期448-451,463,共5页 Oncology Progress
关键词 HER-2 晚期乳腺癌 耐药
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Kaori Fujimoto-Ouchi, Fumiko S, Kaname Y, et al. Pre- clinical study of prolonged administration of trastuzum- ab as combination therapy after disease progression dur- ing trastuzumab monotherapy[J]. Cancer Chemother Pharmacol, 2010, 66(2): 269-276.
  • 2Extra JM, Antoine EC, Vincent-Salomon A, et al. Effica- cy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the ob- servational Hermine study[J]. Oncologist, 2010, 15(8): 799-809.
  • 3Von Minckwitz G1, du Bois A, Schmidt M, et al. Trastu- zumab Beyond Progression in Human Epidermal Growth Factor Receptor 2 - Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study[J]. J Clin Oncol, 2009, 27(12): 1999- 2006.
  • 4Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I re- ceptor signaling and resistance to trastuzumab (Her- ceptin) [J]. J Natl Cancer Inst, 2011, 93(24): 1852-1857.
  • 5Cameron D, Casey M, Press M, et al. A phase III ran- domized comparison of lapatinib plus capecitabine ver- sus capecitabine alone in women with advanced breast cancer that has progressed on trasutzumab: updated effi- cacy andbiomarker analyses[J]. Breast Cancer Res Treat, 2008, 112(3): 533-543.
  • 6Cameron D, Casey M, Oliva C, et al. Lapatinib Plus Capecitabine in Women with HER-2 - Positive Ad- vanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial[J]. The Oncologist, 2010, 15 (9):924-934.
  • 7Junttila TT, Li G, Parsons K, et al. Trastuzumab-DMl(T- DM1) retains all themechanisms of action of trastuzum. ab and efficiently inhibits growth of lapatinib insensitive breast cancer[J]. Breast Cancer Res Treat, 2011, 128(2): 347- 356.
  • 8Verma S, Miles D, Gianni L, et al. Trastuzumab emtan- sine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
  • 9Nahta R, Yuan LX, Du Y, et al. Lapatinib induces apop- tosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor 1 signaling[J]. Mol Cancer Ther, 2007, 6(2): 667-674.
  • 10Mukherjee A, Dhadda AS, Shehata M, et al. Lapatinib: A tyrosine kinase inhibitor with a clinicalrole in breast cancer[J]. Expert Opin Pharmaco ther, 2007, 8(13): 2189-2204.
癌症进展
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部